New drug remibrutinib tested for chronic hives relief in Real-World study
NCT ID NCT07408219
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 350 people with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will survey patients and their doctors to see how well the drug controls symptoms and how satisfied patients are. The goal is to understand real-world effectiveness, not to prove the drug works in a controlled setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remibrutinib
- What this could lead to
- If successful, this could show that remibrutinib helps control hives and improves quality of life in real-world settings.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It is early-stage real-world data, not a definitive test of effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
RECRUITINGEast Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diet tame chronic hives in teens?
- Can a new pill silence the itch of chronic hives?
- New drug aims to quiet chronic hives
- New pill for chronic hives enters first human tests
- New pill for chronic hives tested in everyday clinics
- New hope for chronic hive sufferers: phase 3 drug trial shows promise